Aprea Therapeutics, Inc. SEC Filings

Aprea Therapeutics (APRE) filed its Q3 2025 10‑Q, reporting a net loss of $2,972,410 and cash and cash equivalents of $13,718,052. Operating expenses declined to $3,119,236 from $4,451,637 a year ago as both R&D and G&A trended lower. Interest income was $150,669.

The company stated that its September 30, 2025 cash balance will not fund operations for at least twelve months from issuance of the financial statements, indicating substantial doubt about continuing as a going concern. To bolster liquidity, Aprea raised approximately $0.8 million net during the nine months via its at‑the‑market program, issuing 468,567 shares. For the nine months, net loss was $10,143,939.

Program updates included setting the recommended Phase 2 dose of ATRN‑119 at 1,100 mg once daily and a strategic pause in further monotherapy enrollment while exploring combination studies. Common shares outstanding were 6,310,673 as of November 11, 2025.

Aprea Therapeutics, Inc. furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and provided an operations update. The release is attached as Exhibit 99.1.

The company also filed an updated corporate presentation as Exhibit 99.2. Per General Instruction B.2, the Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under Section 18, nor incorporated by reference unless expressly stated.

Aprea Therapeutics (APRE) reported an other event, stating it issued a press release with a clinical update from the ACESOT-1051 trial that shows early signals of activity for its WEE1 kinase inhibitor, APR-1051.

The press release is attached as Exhibit 99.1 and incorporated by reference. This notice informs the market of new clinical observations; detailed results and context are contained in the attached press release.

Aprea Therapeutics (APRE) reported operational updates via Form 8-K. The company announced the recommended Phase 2 dosing for ATRN-119, paused further enrollment in both once-daily and twice-daily dosing arms of ABOYA-119, and is considering additional ATRN-119 development in combination therapies.

The updates were communicated in a press release dated October 15, 2025, and accompanied by a refreshed corporate presentation. Both materials are provided as exhibits to the filing, offering more detail on current development plans and clinical program status.

Sio Capital Management, LLC reports beneficial ownership of 279,369 shares of Aprea Therapeutics common stock, representing 5.05% of the class as of June 30, 2025. The position is held for affiliated funds for which Sio is the registered investment adviser; Sio reports 0 sole voting or dispositive power and 279,369 shared voting and dispositive power.

The 5.05% figure is calculated using 5,525,172 shares outstanding as of April 22, 2025. The filing notes that the general partner and Michael Castor may be deemed to have influence over the accounts that own the shares, while expressly disclaiming beneficial ownership; the filer certifies the shares are held in the ordinary course of business and not to change or influence control.

Aprea Therapeutics reported cash and cash equivalents of $16.5 million and total assets of $17.3 million, with an accumulated deficit of $328.2 million. The company recorded a net loss of $7.17 million for the six months and used $6.8 million of cash in operating activities over the same period. Grant revenue declined to $0.28 million year-to-date, largely from reduced NIH funding. Research and development spending was $4.40 million for six months, driven by ATRN-119 and APR-1051 programs, and the company expects safety/efficacy data in the second half of the year with RP2D decisions expected in the first half of 2026. Management states existing cash is not sufficient to fund operations for at least twelve months and has concluded substantial doubt exists about its ability to continue as a going concern, and is seeking additional funding.

Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.